Chimeric antigen receptor (CAR) T-cell therapy represents a paradigm shift in the treatment of relapsed or refractory haematological cancers by harnessing patients’ own immune cells to target surface ...

Background Chronic hepatitis B virus (HBV) infection disproportionately affects people living with HIV, who are often ...

Introduction Sjögren’s disease (SjD) is a systemic, rheumatic autoimmune disorder evidenced by broad organ-specific ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

Cooperation between Finnish and Chinese research groups has opened up new opportunities for developing treatments targeting aggressive acute lymphoblastic leukaemia (T-ALL). A research group led by ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

A therapy that has revolutionised how we treat blood and skin cancers could become even more effective. Making cancer cells stiffer bolstered the effects of immunotherapy, when the immune system is ...